A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells are involved in immune surveillance of various malignancies, including multiple myeloma (MM).[1][1] IPH2101 is a fully human monoclonal antibody that blocks HLA-C binding KIR2D receptors (KIR2DL/DS-1, -2 -3) expressed on the surface of NK-cells, enhancing their cytotoxicity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171 · cited 1×
“Recent evidence from a randomized phase III study shows that early treatment with lenalidomide and dexamethasone improves time to progression and overall survival in high-‐risk SMM patients when compared to observation(8).”
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Pérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
Paul, S., & Lal, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01124 · Cited by 825
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Metadata
- Authors
- Korde, N., Carlsten, M., Lee, M.-J., Minter, A., Tan, E., Kwok, M., Manasanch, E., Bhutani, M., Tageja, N., Roschewski, M., Zingone, A., Costello, R., Mulquin, M., Zuchlinski, D., Maric, I., Calvo, K. R., Braylan, R., Tembhare, P., Yuan, C., Stetler-Stevenson, M., Trepel, J., Childs, R., & Landgren, O.
- Venue
- Haematologica
- Published
- 2014-03-21
- Volume
- 99
- Issue
- 6
- Pages
- e81-e83
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2018580749
- Cited by
- 131
- References
- 4
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. https://app.cochat.ai/papers/10.3324/haematol.2013.103085
- The paper
- Korde, N., Carlsten, M., Lee, M.-J., Minter, A., Tan, E., Kwok, M., Manasanch, E., Bhutani, M., Tageja, N., Roschewski, M., Zingone, A., Costello, R., Mulquin, M., Zuchlinski, D., Maric, I., Calvo, K. R., Braylan, R., Tembhare, P., Yuan, C., . . . Landgren, O. (2014). A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica. https://doi.org/10.3324/haematol.2013.103085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.